James on for Maury Raycroft's questions to Taysha Gene Therapies Inc (TSHA) leadership • Q2 2025
Question
An analyst from Jefferies asked for expectations regarding the new supplemental REVEAL Part A data planned for Q4, inquiring about the potential granularity of the data and the venue for its release.
Answer
CEO Sean Nolan responded that the data could be presented at both a medical conference and a company-hosted update. He explained that the update will provide a more 'fulsome picture' of the therapy's impact by sharing information on additional milestones and detailing how these gains translate into meaningful improvements in activities of daily living and overall quality of life for patients.